novo nordisk cagrilintide Stock Tumbles on CagriSema Trial Data. Why Investors Have Doubts Another obesity contender just raised
Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control Weight loss: New drug CagriSema leads to 14% weight loss in trial Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment ADA 2025: CagriSema Demonstrates Significant Weight Loss in REDEFINE Clinical Trials Pharmacy Times
Pay in 4 interest-free payments of $6.46 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
:max_bytes(150000):strip_icc()/GettyImages-2197227432-6dabff12e088403c8032fbae8a53811d.jpg)
